Prevalence of Elevated Luteinizing Hormone (LH)/Follicle Stimulating Hormone (FSH) Ratio in Polycystic Ovary Syndrome (PCOS) Women Among Local Population
Keywords:
PCOS, gonadotropin, BMIAbstract
Objective: To assess the frequency of elevated LH/FSH ratio>1 in women with polycystic ovary syndrome among local population.
Study Design: Cross-sectional study.
Methodology: This cross sectional study was carried out at two tertiary care hospitals in Karachi during October 2010 to Feb 2011. A total of 163 PCOS women of reproductive age (18-40years) fulfilling revised Rotterdam 2003 criteria were studied. The data recorded on a prescribed proforma include current age, age at menarche, menstrual irregularities, presence of hirsuitism, acne, infertility, familial nature, blood pressure, BMI, waist to hip ratio. Blood sample for gonadotropin assay were taken in random state on specific dates of menstrual cycle (day 6th to day 30th) in gel tube. Hormonal assay were performed using chemiluminescent immunoassay.
Results: Mean age of presentation of PCOS subjects was 24.88±5.35 years. Menstrual irregularities (99%) were the commonest presentation followed by acne (88%), hirsuitism (71%) and infertility (62%). A high frequency (>71%) of elevated LH/FSH > 1ratio was observed among local population. Conclusion: The present study concludes that elevated LH/FSH ratio>1 is a characteristic finding ofPakistani population of PCOS (present in = 71% of patients) and with proper sampling dates can be used as diagnostic
tool for establishing the diagnosis ofPCOS.
Downloads
References
Kelestimur F, Unluhizarci K. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus. Fertil Steril 2006; 86:405-10.
Richardson MR. Current perspectives in polycystic ovary syndrome. Am Fam Physician 2003; 68:697-704. 3 Najem FI, Elmehdawi RR, Swalem AM. Clinical and Biochemical Characteristics of Polycystic Ovary Syndrome in Benghazi-Libya; A Retrospective study.
Libyan J Med 2008; 3:71-4.
Jakubowski L. Genetic aspects of polycystic ovary syndrome. Endokrynol Pol 2005; 56:285-93. 5 Bloom MS, Schisterman EF, Hediger ML. Selecting controls is not selecting "normals": design and analysis issues for studying the etiology of polycystic ovary
syndrome. Fertil Steril 2006; 86:1-12.
Norman RJ, Wu R, Stankiewicz MT. Polycystic ovary
syndrome. MedJ Aust2004; 180:132-7.
Meisler JG. Toward optimal health: The experts discuss polycystic ovary syndrome. J Womens Health Gend Based Med 2002; 11:579-84.
Salmi DJ, Zisser HC, Jovanovic L. Screening for and treatment of polycystic ovary syndrome in teenagers.
Exp Biol Med 2004; 229:369-77.
Gutman G, Geva E, Lessing JB, Amster R. Long-Term Health Consequences ofPolycystic Ovaries Syndrome: Metabolic, Cardiovascular and Oncological Aspects. Harefuah 2007; 146:889-93.
Rasgon NL, Rao RC, Hwang S, Altshuler LL, Elman S, Zuckerbrow-Miller J, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003; 74:299-304.
Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005; 90:4650-8.
Taylor AE. Gonadotropin dysfunction in women with polycystic ovary syndrome. Fertil Steril 2006; 86:12.
Banaszewska B, Spaczynski RZ, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo-and hyperinsulinemia.5 Chemoprevention of lung cancer:from concept to reality 2003; 15:131-4.
Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem 2006; 43:217-9.
Fauser BC, Pache TD, Hop WC, de Jong FH, Dahl KD. The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates*. ClinEndocrinol 1992; 37:445-52.
Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2248-56.
Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone /follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi Med J 2007; 28:1039-43.
Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of Polycystic Ovarian Syndrome in Indian
Adolescents. J Pediatr Adolesc Gynecol 2011; 24:223-7.
Kumarapeli V, Seneviratne Rde A, Wijeyaratne CN, Yapa RM, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol 2008; 168:321-8.
Setj i TL, Brown AJ. Comprehensive clinical management ofpolycystic ovary syndrome. Minerva Med 2007; 98:175-89.
Monga A, Dobb S. The normal menstural cycle. In: Monga S, editor. Gynaecology by Ten teacher. 18 ed; 2006: 32-42.
Arulkumaran S, Symonds I. Polycystic ovarian syndrome. In: Symonds I, Fowlie A, editors. Oxford Hand book
of obstetric and Gynaecology 2 ed. UK; 2005:541-7.
Iwasa T, Matsuzaki T, Murakami M, Shimizu F, Kuwahara A, YasuiT, etaL ReproduribilityofTuteinizing hormone hypersecretion
in different phases of the menstrual cycle in polycystic ovary syndrome. J Obstet Gynaecol Res 2009; 35:514-9.
Hsu MI, Liou TH, Liang SJ, Su HW, Wu CH, Hsu CS. Inappropriate gonadotropin secretion in polycystic ovary
syndrome. Fertil Steril 2009; 91:1168-74.
Hendriks ML, Brouwer J, Hompes PGA, Homburg R, Lambalk CB. LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo/amenorrhoea. Reprod Biomed Onlin 2008; 16:765-71.
Lakhani K, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovaries. Br J Radiol 2002; 75:9-16.
Rickenlund A, Thoren M, Caristrom K, Von Schoultz BO, Hirschberg AL. Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes. J Clin Endocrinol Metab 2004; 89:702-7.
Garde AH, Hansen AM, Skovgaard LT, Christensen JM. Seasonal and biological variation of blood concentrations of total cholesterol, dehydroepiandrosterone sulfate, hemoglobin A1c, IgA, prolactin, and free testosterone in healthy women. Clin Chem 2000; 46:551-9.
MassafTa C, De Felice C, Agnusdei DP, Gioia D, Bagnoli F. Androgens and osteocalcin during the menstrual cycle. J Clin Endocrinol Metab 1999; 84:971-4.
Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome* 1. Fertil Steril 2000; 73:724-9. '
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Shehla Haider , Nighat Manan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. 
